Zepbound vs Wegovy: A two horse race
Podcast: BioSpacePublished On: Wed Nov 15 2023
Description: Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class. Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
The note was deleted
The note was saved
Your message was sent